Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | KMO | O15229 | 1/20 | 0.60 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.59 |
| ▸ | FEN1 | P39748 | 1/20 | 0.59 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | CFD | P00746 | 1/20 | 0.56 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.53 |
| ▸ | AOC2 | O75106 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | F2R | P25116 | 1/20 | 0.52 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25700071 | 0.94 | ALDH1A1 (0.68) | HDAC8KDM4EALDH1A1KMOERCC5 | |
| SCHEMBL28254875 | 0.94 | ALDH1A1 (0.68) | HDAC8KDM4EALDH1A1KMOERCC5 | |
| SCHEMBL3793085 | 0.91 | ALDH1A1 (0.59) | HDAC8KDM4EALDH1A1NR1H4EPHX2 | |
| SCHEMBL28047591 | 0.90 | HDAC8 (0.55) | HDAC8KDM4EALDH1A1KMOERCC5 | |
| SCHEMBL31148960 | 0.86 | DHODH (0.55) | HDAC8KDM4EALDH1A1KMOERCC5 | |
| SCHEMBL18376133 | 0.84 | CFD (0.64) | HDAC8KDM4EALDH1A1KMOERCC5 | |
| SCHEMBL77384 | 0.83 | ALDH1A1 (0.76) | HDAC8KDM4EALDH1A1AOC2 | |
| SCHEMBL10363097 | 0.82 | HDAC8 (1.00) | HDAC8KDM4EKMOERCC5FEN1 | |
| SCHEMBL1706875 | 0.82 | NPC1 (0.67) | HDAC8KDM4EALDH1A1ERCC5FEN1 | |
| SCHEMBL5951312 | 0.81 | HDAC8 (0.66) | HDAC8ALDH1A1KMOERCC5FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559455-B2 | Compound as a UBR box domain ligand | AUTOTAC INC. (KR) | 2026-02-24 | — | — | US | disclosed |
| US-11945797-B2 | 1-cyano-pyrrolidine derivatives as dub inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | disclosed |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | AUTOTAC INC. (KR) | 2023-06-08 | — | — | US | disclosed |
| WO-2023074936-A1 | BIFUNCTIONAL COMPOUND USING UBR BOX DOMAIN-BINDING LIGAND | 주식회사 오토텍바이오 | 2023-05-04 | — | — | WO | disclosed |
| EP-4144722-A1 | COMPOUND AS UBR BOX DOMAIN LIGAND | Autotac Inc. (KR) | 2023-03-08 | — | — | EP | disclosed |
| US-20220177451-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-09 | — | — | US | disclosed |
| US-11352339-B2 | 1-cyano-pyrrolidine derivatives as DUB inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-07 | — | — | US | disclosed |
| EP-3433246-B1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-05-04 | — | — | EP | disclosed |
| CN-108884068-B | 1-cyano-pyrrolidine derivatives as DUB inhibitors | 特殊治疗有限公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-108212094-B | Double-pyrazole functionalized SBA-15 mesoporous material and preparation method and application thereof | 上海海关工业品与原材料检测技术中心 | 2020-11-06 | — | — | CN | disclosed |
| US-7572822-B2 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20090074890-A1 | Substituted Triazoles as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2009-03-19 | — | — | US | disclosed |
| US-20090068180-A1 | COMPOSITIONS AND METHODS FOR TREATING IMMUNOLOGICAL AND INFLAMMATORY DISEASES AND DISORDERS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-03-12 | — | — | US | disclosed |
| WO-2009032972-A1 | COMPOSITIONS AND METHODS FOR TREATING IMMUNOLOGICAL AND INFLAMMATORY DISEASES AND DISORDERS | LEXICON PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| EP-2010501-A2 | IMIDAZOLE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| US-7459475-B2 | Substituted triazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080171777-A1 | Biaryl substituted triazoles as sodium channel blockers | MERCK SHARP & DOHME LLC | 2008-07-17 | — | — | US | disclosed |
| US-7326726-B2 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO., INC. (US) | 2008-02-05 | — | — | US | disclosed |
| WO-2007100617-A2 | IMIDAZOLE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070208063-A1 | Imidazole-based compounds, compositions comprising them and methods of their use | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068180-A1 | COMPOSITIONS AND METHODS FOR TREATING IMMUNOLOGICAL AND INFLAMMATORY DISEASES AND DISORDERS | ASAH2, SGMS1, SMPD1 | HDAC8 1104/4885KDM4E 2549/4885ALDH1A1 1316/4885 |
| US-20070208063-A1 | Imidazole-based compounds, compositions comprising them and methods of their use | TPMT, INMT, NFKBIA | HDAC8 152/4885KDM4E 2146/4885ALDH1A1 808/4885 |
| US-11352339-B2 | 1-cyano-pyrrolidine derivatives as DUB inhibitors | USP30, USP28, USP1 | HDAC8 1633/4885KDM4E 298/4885ALDH1A1 719/4885 |
| US-20090074890-A1 | Substituted Triazoles as Sodium Channel Blockers | TRPV1, SCN3A, SCN5A | HDAC8 473/4885KDM4E 2395/4885ALDH1A1 1306/4885 |
| US-20080171777-A1 | Biaryl substituted triazoles as sodium channel blockers | SCN3A, TRPV1, SCN1B | HDAC8 426/4885KDM4E 2772/4885ALDH1A1 903/4885 |
| US-20220177451-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | USP30, USP28, USP1 | HDAC8 1633/4885KDM4E 298/4885ALDH1A1 719/4885 |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | UBR4, UBQLN2, UBTF | HDAC8 1666/4885KDM4E 1340/4885ALDH1A1 2317/4885 |
| US-11945797-B2 | 1-cyano-pyrrolidine derivatives as dub inhibitors | USP30, USP28, USP1 | HDAC8 1633/4885KDM4E 298/4885ALDH1A1 719/4885 |
| US-12559455-B2 | Compound as a UBR box domain ligand | UBR4, UBTF, UBQLN1 | HDAC8 606/4885KDM4E 707/4885ALDH1A1 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.